• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中枢性抗高血压药物:最新进展

Centrally acting antihypertensive agents: an update.

作者信息

Sica Domenic A

机构信息

Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0160, USA.

出版信息

J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. doi: 10.1111/j.1524-6175.2007.07161.x.

DOI:10.1111/j.1524-6175.2007.07161.x
PMID:17485976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8110163/
Abstract

Centrally acting agents stimulate alpha(2) receptors and/or imadozoline receptors on adrenergic neurons situated within the rostral ventrolateral medulla and, in so doing, sympathetic outflow is reduced. Centrally acting agents also stimulate peripheral alpha(2) receptors, which, for the most part, is of marginal clinical significance. Central a agonists have had a lengthy history of use, starting with alpha-methyldopa, which has had a dramatic decline in use, in part, because of bothersome side effects. Patients who require multidrug therapy with otherwise resistant hypertension, such as diabetic and/or renal failure patients, are typically responsive to these drugs, as are patients with sympathetically driven forms of hypertension. Perioperative forms of hypertension respond well to clonidine, a circumstance where the additional anesthesia- and analgesia-sparing effects of this drug may offer additional clinical benefits. Clonidine can be used adjunctively with other more traditional therapies in heart failure, particularly when hypertension is present. Sustained-release moxonidine, however, is associated with early mortality and morbidity when used in patients with heart failure. Escalating doses of drugs in this class often give rise to salt and water retention, in which case diuretic therapy becomes a valuable adjunctive therapy.

摘要

中枢作用药物刺激位于延髓头端腹外侧的肾上腺素能神经元上的α₂受体和/或咪唑啉受体,从而减少交感神经输出。中枢作用药物还刺激外周α₂受体,在很大程度上,这在临床上意义不大。中枢性α激动剂有很长的使用历史,始于α-甲基多巴,其使用量已大幅下降,部分原因是其令人烦恼的副作用。需要联合多种药物治疗的顽固性高血压患者,如糖尿病和/或肾衰竭患者,通常对这些药物有反应,交感神经驱动型高血压患者也是如此。围手术期高血压对可乐定反应良好,在这种情况下,该药物额外的麻醉和镇痛作用可能会带来更多临床益处。可乐定可与心力衰竭的其他更传统疗法联合使用,尤其是在存在高血压时。然而,缓释莫索尼定用于心力衰竭患者时与早期死亡率和发病率相关。这类药物剂量增加往往会导致盐和水潴留,在这种情况下,利尿剂治疗成为一种有价值的辅助治疗。

相似文献

1
Centrally acting antihypertensive agents: an update.中枢性抗高血压药物:最新进展
J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. doi: 10.1111/j.1524-6175.2007.07161.x.
2
[Centrally acting sympathetic inhibitors for therapy of patients with hypertension].[用于高血压患者治疗的中枢性交感神经抑制剂]
Nihon Rinsho. 1997 Aug;55(8):2081-5.
3
Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.利美尼定和莫索尼定中枢降压作用相关受体的分析
Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):262-71. doi: 10.1007/pl00005351.
4
Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?中枢作用的咪唑啉I1受体激动剂:它们在高血压管理中有一席之地吗?
Am J Cardiovasc Drugs. 2001;1(5):321-6. doi: 10.2165/00129784-200101050-00002.
5
New central mediators as targets of centrally acting antihypertensive drugs.新型中枢介质作为中枢性抗高血压药物的作用靶点
Clin Exp Hypertens. 1996 Apr-May;18(3-4):291-303. doi: 10.3109/10641969609088964.
6
Why imidazoline receptor modulator in the treatment of hypertension?为什么咪唑啉受体调节剂可用于治疗高血压?
Ann N Y Acad Sci. 1995 Jul 12;763:659-72. doi: 10.1111/j.1749-6632.1995.tb32460.x.
7
Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents.
Ann N Y Acad Sci. 1999 Jun 21;881:279-86. doi: 10.1111/j.1749-6632.1999.tb09370.x.
8
A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.一种控制高血压的新作用机制:莫索尼定作为一种选择性I1-咪唑啉激动剂。
Cardiovasc Drugs Ther. 1994 Mar;8 Suppl 1:27-41. doi: 10.1007/BF00877082.
9
Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.作用于咪唑啉和肾上腺素能受体药物的临床药理学。可乐定、莫索尼定、利美尼定和阿替洛尔的研究。
Ann N Y Acad Sci. 1995 Jul 12;763:673-8. doi: 10.1111/j.1749-6632.1995.tb32461.x.
10
Comparison of the baroreceptor-heart rate reflex effects of moxonidine, rilmenidine and clonidine in conscious rabbits.莫索尼定、利美尼定和可乐定对清醒家兔压力感受器-心率反射作用的比较。
J Auton Nerv Syst. 1998 Oct 15;72(2-3):195-204. doi: 10.1016/s0165-1838(98)00105-2.

引用本文的文献

1
Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.探索神经退行性疾病的免疫治疗策略:聚焦亨廷顿舞蹈症和朊病毒病
Acta Pharmacol Sin. 2025 Jun;46(6):1511-1538. doi: 10.1038/s41401-024-01455-w. Epub 2025 Jan 31.
2
Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review.接种 COVID-19 疫苗后出现的体位性心动过速综合征:系统评价。
BMC Cardiovasc Disord. 2024 Nov 13;24(1):643. doi: 10.1186/s12872-024-04315-x.
3
Neuroprotective actions of norepinephrine in neurological diseases.去甲肾上腺素在神经疾病中的神经保护作用。
Pflugers Arch. 2024 Nov;476(11):1703-1725. doi: 10.1007/s00424-024-02999-w. Epub 2024 Aug 13.
4
Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement.用选择性咪唑啉受体激动剂莫索尼定靶向交感神经系统治疗高血压:国际立场声明。
J Hypertens. 2024 Dec 1;42(12):2025-2040. doi: 10.1097/HJH.0000000000003769. Epub 2024 Sep 23.
5
An Actual Perspective on I1-Imidazoline Agonists in Blood Pressure Control. Results of a Multicentric Observational Prospective Study.I1-咪唑啉激动剂在血压控制中的实际观察。一项多中心前瞻性观察研究的结果。
Maedica (Bucur). 2023 Dec;18(4):547-554. doi: 10.26574/maedica.2023.18.4.547.
6
European position paper on polypharmacy and fall-risk-increasing drugs recommendations in the World Guidelines for Falls Prevention and Management: implications and implementation.欧洲关于药物滥用和增加跌倒风险药物的立场文件,以及世界跌倒预防和管理指南中的建议:影响和实施。
Eur Geriatr Med. 2023 Aug;14(4):649-658. doi: 10.1007/s41999-023-00824-8. Epub 2023 Jul 15.
7
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions.血管功能和高血压中的信号通路:分子机制和治疗干预。
Signal Transduct Target Ther. 2023 Apr 20;8(1):168. doi: 10.1038/s41392-023-01430-7.
8
Neurogenic Hypertension, the Blood-Brain Barrier, and the Potential Role of Targeted Nanotherapeutics.神经原性高血压、血脑屏障与靶向纳米疗法的潜在作用。
Int J Mol Sci. 2023 Jan 22;24(3):2213. doi: 10.3390/ijms24032213.
9
Prion therapeutics: Lessons from the past.朊病毒治疗学:过去的经验教训。
Prion. 2022 Dec;16(1):265-294. doi: 10.1080/19336896.2022.2153551.
10
Guanabenz ameliorates disease in vanishing white matter mice in contrast to sephin1.胍那苄改善进行性白色物质脑白质营养不良症小鼠的疾病,与 sephin1 相反。
Ann Clin Transl Neurol. 2022 Aug;9(8):1147-1162. doi: 10.1002/acn3.51611. Epub 2022 Jul 1.

本文引用的文献

1
Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study.可乐定可减少近端空肠造口术患者的腹泻和钠流失:一项对照研究。
JPEN J Parenter Enteral Nutr. 2006 Nov-Dec;30(6):487-91. doi: 10.1177/0148607106030006487.
2
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.可乐定对肝硬化腹水患者利尿反应及交感神经系统激活的影响。
Hepatology. 2006 Oct;44(4):844-9. doi: 10.1002/hep.21355.
3
Moxonidine: a review of its use in essential hypertension.莫索尼定:其在原发性高血压治疗中的应用综述
Drugs. 2006;66(4):477-96. doi: 10.2165/00003495-200666040-00006.
4
Transdermal clonidine: therapeutic considerations.透皮可乐定:治疗方面的考虑。
J Clin Hypertens (Greenwich). 2005 Sep;7(9):558-62. doi: 10.1111/j.1524-6175.2005.04133.x.
5
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.全国高血压防治联合委员会第七次报告:预防、检测、评估及治疗
Hypertension. 2003 Dec;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. Epub 2003 Dec 1.
6
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).心力衰竭患者中使用缓释莫索尼定进行中枢交感神经抑制的不良死亡率影响(MOXCON研究)
Eur J Heart Fail. 2003 Oct;5(5):659-67. doi: 10.1016/s1388-9842(03)00163-6.
7
Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial.可乐定治疗新发快速性心房颤动的临床评估:一项前瞻性随机临床试验。
Am Heart J. 2001 Aug;142(2):E3. doi: 10.1067/mhj.2001.116761.
8
Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?抗高血压药物对未出生胎儿的影响:已知情况以及这应如何影响处方开具?
Paediatr Drugs. 2000 Nov-Dec;2(6):419-36. doi: 10.2165/00128072-200002060-00002.
9
Rilmenidine: a clinical overview.利美尼定:临床概述。
Am J Hypertens. 2000 Jun;13(6 Pt 2):106S-111S. doi: 10.1016/s0895-7061(00)00226-0.
10
The effect of chronic clonidine administration on salivary glands and caries in the rat.
Caries Res. 2000 Mar-Apr;34(2):194-200. doi: 10.1159/000016589.